Avacta Group base_Aktie

pages_aktie_[isin]_directordealings_0

components_InsiderTable_9

Avacta Group

components_Profile_InsiderKeyStats__1
components_Profile_InsiderKeyStats__2
0 GBP
components_Profile_InsiderKeyStats__3
AVCT.L
components_Profile_InsiderKeyStats__4
GB00BYYW9G87
components_Profile_InsiderKeyStats__5
A2ADP0
components_Profile_InsiderKeyStats_9
1,00 GBP
components_Profile_InsiderKeyStats_10
1,00 GBP
components_Profile_InsiderKeyStats_11
1,00 GBP

pages_aktie_[isin]_directordealings_2

pages_insiderkaeufe_[isin]__0 pages_insiderkaeufe_[isin]__1pages_insiderkaeufe_[isin]__2 pages_insiderkaeufe_[isin]__3pages_insiderkaeufe_[isin]__4 pages_insiderkaeufe_[isin]__5

pages_aktie_[isin]_directordealings_3

Avacta Group PLC is a British company specializing in the development of innovative solutions for biotechnology and diagnostics. It was founded in 2004 by Eliot Forster and is headquartered in Wetherby, West Yorkshire. Avacta's history began with the development of Affimer technology, which offers an alternative to conventional antibodies. Affimers are synthetic peptides with high binding affinity to biological molecules, making them important tools for biomedical research and diagnostic applications. The company had limited resources in its early years, and it took several years to complete the development of Affimer technology. In recent years, Avacta has expanded its business model by offering licensed services to pharmaceutical companies. The company provides innovative screening methods and drug discovery tools based on Affimer technology. Avacta has partnerships with major companies such as LG Chem, Moderna, and Wockhardt. The partnership with LG Chem aims to use the platform technology for the development of Covid-19 therapeutics, while the collaboration with Wockhardt focuses on the creation of diagnostic kits and test systems. Avacta's main business areas are biotechnology and diagnostics. The biotechnology division offers screening services for pharmaceutical companies, with a focus on developing higher quality and more efficient antibodies using Affimers, which potentially provide better screening results than traditional antibodies. In the field of diagnostics, the company is working on the development of diagnostic test systems for disease diagnosis. Avacta has started developing diagnostic test kits for Covid-19 that can be used in a laboratory or at home. The company also has a partnership with Adeptrix, a diagnostic tool manufacturing company. Another important area of Avacta is therapeutic applications. Avacta's Affimer technology has already led to new clinical approaches in the development of cancer therapies. Avacta also has a pipeline program of Affimer therapeutics targeting various diseases, from cancer to inflammatory and neurodegenerative diseases. Avacta's products include licensed services for pharmaceutical companies, research kits for Affimer technology, and its own portfolio of Affimer products for various applications in research and diagnostics. The products are exported worldwide, and the company has offices in the United States and South Korea. Overall, Avacta Group PLC has become a major player in the biotechnology and diagnostics industry by expanding its Affimer technology to various applications. Partnerships with major pharmaceutical companies and the development of diagnostic test systems for Covid-19 have brought the company into the public eye and contribute to strengthening its position as a leading provider of Affimer technology in the industry.

components_InsiderFAQ__11

components_InsiderFAQ__0

components_InsiderFAQ__1

components_InsiderFAQ__2

components_InsiderFAQ__3
components_InsiderFAQ__4

components_InsiderFAQ__5

components_InsiderFAQ__6

components_InsiderFAQ__7

components_InsiderFAQ__8

components_InsiderFAQ__9

components_InsiderFAQ__10

components_InsiderArticle__1

components_InsiderArticle__5

components_InsiderArticle__8

components_InsiderArticle__9

components_InsiderArticle__12

components_InsiderArticle__13

components_InsiderArticle__16

components_InsiderArticle__17

components_InsiderArticle__20

components_InsiderArticle__22

components_InsiderArticle__25

components_InsiderArticle__28

components_InsiderArticle__31

components_InsiderArticle__32

components_InsiderArticle__34

components_InsiderArticle__36

components_InsiderArticle__37

components_InsiderArticle__38

components_InsiderArticle__41 components_InsiderArticle__42 components_InsiderArticle__43 components_InsiderArticle__44 components_InsiderArticle__45

components_InsiderArticle__46

  • components_InsiderArticle__48
  • components_InsiderArticle__49

components_InsiderArticle__50

components_InsiderArticle__51

components_InsiderArticle__54

components_InsiderArticle__55

components_InsiderArticle__58

components_InsiderArticle__59

components_InsiderArticle__60

  • components_InsiderArticle__61
  • components_InsiderArticle__62
  • components_InsiderArticle__63
  • components_InsiderArticle__64
  • components_InsiderArticle__65
  • components_InsiderArticle__66

components_InsiderArticle__67

components_InsiderArticle__68

components_InsiderArticle__73

components_InsiderArticle__74

components_InsiderArticle__77

components_InsiderArticle__78

components_InsiderArticle__81

components_InsiderArticle__82

components_InsiderArticle__85

components_InsiderArticle__86 components_InsiderArticle__87. components_InsiderArticle__88

components_InsiderArticle__90

components_InsiderArticle__93

components_InsiderArticle__94

components_InsiderArticle__97

components_InsiderArticle__98

components_InsiderArticle__103

components_InsiderArticle__110

components_InsiderArticle__113

components_InsiderArticle__114

components_InsiderArticle__116

components_InsiderArticle__118 components_InsiderArticle__119 components_InsiderArticle__120

components_InsiderArticle__122

components_InsiderArticle__125

components_InsiderArticle__126

components_InsiderArticle__129

components_InsiderArticle__132

components_InsiderArticle__137

components_InsiderArticle__142

components_InsiderArticle__145

components_InsiderArticle__147

components_InsiderArticle__148

components_InsiderArticle__150

components_InsiderArticle__155

components_InsiderArticle__158

components_InsiderArticle__159

components_InsiderArticle__162

components_InsiderArticle__163

components_InsiderArticle__166

components_InsiderArticle__167

components_InsiderArticle__172

components_InsiderArticle__175

components_InsiderArticle__178

components_InsiderArticle__181

components_InsiderArticle__182

components_InsiderArticle__184

components_InsiderArticle__187

components_InsiderArticle__190

components_InsiderArticle__192

components_DirectorsDealingsText_5

components_InsiderArticle__196

components_InsiderArticle__197

components_InsiderArticle__200

components_InsiderArticle__203

components_InsiderArticle__206

components_InsiderArticle__209

components_InsiderArticle__212

components_InsiderArticle__215 components_DirectorsDealingsText_7 components_InsiderArticle__216 components_InsiderArticle__217